While the primaryendpoints of the two pivotal studies conducted were not met, a secondary analysis of the data demonstrated that a molecule acting specifically on amyloid-beta can slow cognitive decline in patients with mild AD.
The drugmakers reported that their bapineuzumab compound failed to meet two primaryendpoints and, consequently, they decided to discontinue additional Phase III research planned, although follow-up evaluations and final data analyses will be conducted ( back story).